secwatch.observer — SEC 8-K summary
======================================

Issuer:     VACCINEX, INC. (VCNX)
CIK:        0001205922
Form:       8-K
Filed at:   2022-09-13T23:59:59+00:00
Accession:  0001193125-22-243745
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccinex presents neoadjuvant pepinemab combo data at ESMO; triple therapy shows 62.5% pCR in Stage III melanoma
--------------------------------------------------------------------------------

- Triple combination (nivolumab/ipilimumab/pepinemab) achieved 62.5% pathologic complete response (pCR) and 75% major pathologic response.
- Doublet pepinemab/nivolumab showed 25% pCR; pepinemab/ipilimumab 12.5% pCR; nivolumab alone 28.5% pCR.
- Triple combination demonstrated significantly improved recurrence-free survival vs doublets (logrank p=0.0097).
- All patients underwent surgery without delay; Grade 3 AEs were manageable (5/8 in triple arm).
- Correlative biomarker data to be presented at 2022 SITC; further studies needed to confirm durability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1205922/000119312522243745/0001193125-22-243745-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1205922/000119312522243745/d402023d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-243745

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer